PROVIDER PROFILE · NPI 1407808314
Eric Evans
MEDICARE UTILIZATION · PART B · 2024
No data available for this provider in 2024.
PRESCRIBING · PART D · 2024
Total Rx claims
1,951
Beneficiaries
—
Total drug cost
$823K
Distinct drugs
47
Brand share
25.3%
Top prescribed drugs
Trazodone Hcl196 claims
Buspirone Hcl124 claims
Sertraline Hcl118 claims
Clonazepam88 claims
Zolpidem Tartrate83 claims
QUALITY · MIPS · 2024
No data available for this provider in 2024.
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2025
Total received
$1K
Payment records
54
By payment type
Food and Beverage$1K
Education$178
Top paying entities
Food and Beverage$1K
Education$178
REFERRAL NETWORK
Where Eric Evans's patients come from & go
Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 2 inbound referrers · 11 outbound destinations.
Receives referrals from
Inbound — who sends patients here
| Physician | Patients | Visits |
|---|---|---|
| Mako Medical Laboratories, Llc Clinical Laboratory · Raleigh, NC | 139 | 1,096 |
| Nilay Desai Endocrinology · Rocky Mount, NC | 12 | 18 |
Refers patients to
Outbound — where patients go next
| Physician | Patients | Visits |
|---|---|---|
| PREMIER MEDICAL, INC. | 183 | 1,066 |
| NASH HOSPITALS INC | 57 | 134 |
| Mako Medical Laboratories, Llc Clinical Laboratory · Raleigh, NC | 56 | 240 |
| Boice-Willis Clinic, Pa Clinical Laboratory · Rocky Mount, NC | 44 | 108 |
| Laboratory Corporation Of America Holdings Clinical Laboratory · Burlington, NC | 37 | 71 |
| EAST CAROLINA HEALTH - HERITAGE INC | 15 | 28 |
| DIXON, DONOVAN | 15 | 20 |
| BIEBER, GAIL | 13 | 21 |
| Stephen Kinard Podiatry · Tarboro, NC | 12 | 45 |
| OPPORTUNITIES INDUSTRIALIZATION CENTER, INC | 11 | 25 |
| FRITZ, RICHARD | 11 | 19 |
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
CROSS-REFERENCE